

UNCLASSIFIED

Exhibit R-2, RDT&E Budget Item Justification: PB 2020 Defense Health Agency **Date:** February 2019

Appropriation/Budget Activity 0130: <i>Defense Health Program I BA 2: RDT&E</i>					R-1 Program Element (Number/Name) PE 0607100DHA I <i>Medical Products and Capabilities Enhancement Activities</i>							
COST (\$ in Millions)	Prior Years	FY 2018	FY 2019	FY 2020 Base	FY 2020 OCO	FY 2020 Total	FY 2021	FY 2022	FY 2023	FY 2024	Cost To Complete	Total Cost
Total Program Element	84.838	13.438	15.714	16.819	-	16.819	17.215	17.619	17.971	18.330	Continuing	Continuing
377A: <i>GDF-Medical Products and Capabilities Enhancement Activities</i>	81.120	13.438	15.714	16.819	-	16.819	17.215	17.619	17.971	18.330	Continuing	Continuing
457A: <i>AF Advanced Technology Development – Rapid Technology Transition</i>	1.336	0.000	0.000	0.000	-	0.000	0.000	0.000	0.000	0.000	Continuing	Continuing
700A: <i>CSI - Congressional Special Interests</i>	2.382	0.000	0.000	0.000	-	0.000	0.000	0.000	0.000	0.000	Continuing	Continuing

A. Mission Description and Budget Item Justification

Guidance for Development of the Force-Medical Products and Capabilities Enhancement Activities: Funds will support (1) developmental upgrades to medical systems and products that have been fielded, are routinely used in a fixed facility, or that have been approved for full-rate production and for which procurement funding is anticipated in the current fiscal year or subsequent fiscal years, (2) testing and evaluation supporting the enhancement of fielded or procured medical systems/products and medically-related information technology systems, (3) assessment of fielded medical products or medical practices in order to identify the need/opportunity for changes, and (4) analyses of clinical intervention outcomes to enhance and improve military unique Clinical Practice Guidelines. Efforts address the Military Health System Concept of Operations documents and follow-on Capabilities Based Assessments/Joint Capability Documents, appropriate Component requirements, legislative and Executive directives (e.g., National Research Action Plan, Precision Medicine Initiative, Office of Management and Budget Combat Casualty Care Assessment, National Defense Authorization Acts, etc.), and others as appropriate.

B. Program Change Summary (\$ in Millions)	FY 2018	FY 2019	FY 2020 Base	FY 2020 OCO	FY 2020 Total
Previous President's Budget	13.438	15.714	16.819	-	16.819
Current President's Budget	13.438	15.714	16.819	-	16.819
Total Adjustments	0.000	0.000	0.000	-	0.000
• Congressional General Reductions	-	-			
• Congressional Directed Reductions	-	-			
• Congressional Rescissions	-	-			
• Congressional Adds	-	-			
• Congressional Directed Transfers	-	-			
• Reprogrammings	-	-			
• SBIR/STTR Transfer	-	-			

UNCLASSIFIED

Exhibit R-2, RDT&E Budget Item Justification: PB 2020 Defense Health Agency		Date: February 2019
Appropriation/Budget Activity 0130: Defense Health Program / BA 2: RDT&E		R-1 Program Element (Number/Name) PE 0607100DHA / Medical Products and Capabilities Enhancement Activities
Change Summary Explanation FY 2016: Realignment from Defense Health Program, Research, Development, Test and Evaluation (DHP RDT&E), PE 0607100-Medical Products and Capabilities Enhancement Activities (-\$1.304 million) to DHP RDT&E PE 0605502-Small Business Innovation Research (SBIR) / Small Business Technology Transfer (STTR) Program (+\$1.304 million). FY 2017: Realignment from Defense Health Program, Research, Development, Test and Evaluation (DHP RDT&E), Program Element (PE) PE 0607100-Medical Products and Capabilities Enhancement Activities (-\$2.291 million) to DHP O&M Account, Budget Activity Group (BAG) 3 - Private Sector Caree (+\$2.291 million). FY 2017: Realignment from Defense Health Program, Research, Development, Test and Evaluation (DHP RDT&E), PE 0607100-Medical Products and Capabilities Enhancement Activities (-\$0.358 million) to USU DHP RDT&E PE 0603115 Breast, GYN and Prostate Cancer Centers of Excellence (+\$0.358 million). FY 2018: Realignment from DHP RDTE PE 0607100-Medical Products and Capabilities Enhancement Activities, Project 377 GDF (-\$1.500 million) to DHP RDTE PE 0603115-Medical Technology Development, Uniformed Services University, Project 478 Applied Proteogenomics Organization Learning and Outcomes (APOLLO) Consortium (+\$1.500 million) to support the White House-directed Cancer Moonshot initiative.		

UNCLASSIFIED

Exhibit R-2A, RDT&E Project Justification: PB 2020 Defense Health Agency										Date: February 2019		
Appropriation/Budget Activity 0130 / 2					R-1 Program Element (Number/Name) PE 0607100DHA / <i>Medical Products and Capabilities Enhancement Activities</i>				Project (Number/Name) 377A / <i>GDF-Medical Products and Capabilities Enhancement Activities</i>			
COST (\$ in Millions)	Prior Years	FY 2018	FY 2019	FY 2020 Base	FY 2020 OCO	FY 2020 Total	FY 2021	FY 2022	FY 2023	FY 2024	Cost To Complete	Total Cost
377A: <i>GDF-Medical Products and Capabilities Enhancement Activities</i>	81.120	13.438	15.714	16.819	-	16.819	17.215	17.619	17.971	18.330	Continuing	Continuing

A. Mission Description and Budget Item Justification
 The goal of the Medical Products and Capabilities Enhancement Activity is to test, evaluate, and support enhancement of existing medical products and medically-related IT systems within the areas of medical simulation, infectious disease, tactical combat casualty care, military operational medicine, and clinical and rehabilitative medicine.

<u>B. Accomplishments/Planned Programs (\$ in Millions)</u>	FY 2018	FY 2019	FY 2020
<i>Title:</i> 377A: GDF – Medical Products and Capabilities Enhancement Activities <i>Description:</i> Provide support for developmental efforts to upgrade medical products and capabilities that have been fielded or have received approval for full rate production and anticipate production funding in the current or subsequent fiscal year. <i>FY 2019 Plans:</i> Funds will be used to enhance, modify, upgrade, test, and evaluate fielded medical materiel and practices. <i>FY 2020 Plans:</i> FY 2020 plans continue efforts as outlined in FY 2019. <i>FY 2019 to FY 2020 Increase/Decrease Statement:</i> Pricing adjustment.	13.438	15.714	16.819
Accomplishments/Planned Programs Subtotals	13.438	15.714	16.819

C. Other Program Funding Summary (\$ in Millions)
 N/A

Remarks

D. Acquisition Strategy
 Integrate product improvements and enhancements resulting from post marketing studies and surveillance.

UNCLASSIFIED

Exhibit R-2A, RDT&E Project Justification: PB 2020 Defense Health Agency		Date: February 2019
Appropriation/Budget Activity 0130 / 2	R-1 Program Element (Number/Name) PE 0607100DHA / <i>Medical Products and Capabilities Enhancement Activities</i>	Project (Number/Name) 377A / <i>GDF-Medical Products and Capabilities Enhancement Activities</i>
E. Performance Metrics <p>Performance is measured based on the number of products for which testing either certifies use in a given environment (e.g., sufficiently ruggedized, airworthiness testing) and/or results in a recommendation of a specific product, and delivery of an enhanced product. The benchmark performance metric for research supported in this PE will be the enhancement of a maturity level that is typical of TRL 9.</p>		

UNCLASSIFIED

Exhibit R-2A, RDT&E Project Justification: PB 2020 Defense Health Agency										Date: February 2019		
Appropriation/Budget Activity 0130 / 2					R-1 Program Element (Number/Name) PE 0607100DHA / <i>Medical Products and Capabilities Enhancement Activities</i>				Project (Number/Name) 457A / <i>AF Advanced Technology Development – Rapid Technology Transition</i>			
COST (\$ in Millions)	Prior Years	FY 2018	FY 2019	FY 2020 Base	FY 2020 OCO	FY 2020 Total	FY 2021	FY 2022	FY 2023	FY 2024	Cost To Complete	Total Cost
457A: <i>AF Advanced Technology Development – Rapid Technology Transition</i>	1.336	0.000	0.000	0.000	-	0.000	0.000	0.000	0.000	0.000	Continuing	Continuing
A. Mission Description and Budget Item Justification Air Force - Medical Products and Capabilities Enhancement Activities: Funds support a developmental upgrade to a medical product that has been fielded and for which procurement funding is anticipated subsequent fiscal years.												
B. Accomplishments/Planned Programs (\$ in Millions)									FY 2018	FY 2019	FY 2020	
Title: AF Advanced Technology Development – Rapid Technology Transition									0.000	-	-	
Description: Provide support for developmental efforts to upgrade medical products and capabilities that have been fielded or have received approval for full rate production and anticipate production funding in the current or subsequent fiscal year.												
Accomplishments/Planned Programs Subtotals									0.000	-	-	
C. Other Program Funding Summary (\$ in Millions) N/A Remarks \$1.1M FY15/17 Defense Health Program – Air Force Procurement funds												
D. Acquisition Strategy Cost-plus Fixed Fee contract award to performer via the Army-Natick Soldier Systems Research Development and Execution Center contracting activity.												
E. Performance Metrics N/A												

UNCLASSIFIED

Exhibit R-2A, RDT&E Project Justification: PB 2020 Defense Health Agency										Date: February 2019		
Appropriation/Budget Activity 0130 / 2					R-1 Program Element (Number/Name) PE 0607100DHA / <i>Medical Products and Capabilities Enhancement Activities</i>				Project (Number/Name) 700A / <i>CSI - Congressional Special Interests</i>			
COST (\$ in Millions)	Prior Years	FY 2018	FY 2019	FY 2020 Base	FY 2020 OCO	FY 2020 Total	FY 2021	FY 2022	FY 2023	FY 2024	Cost To Complete	Total Cost
700A: <i>CSI - Congressional Special Interests</i>	2.382	0.000	0.000	0.000	-	0.000	0.000	0.000	0.000	0.000	Continuing	Continuing

A. Mission Description and Budget Item Justification
 No FY 2017 DHP Congressional Special Interest (CSI) funding is directed toward core research initiatives in Program Element (PE) 0607100 - Medical Products and Capabilities Enhancement Activities.

B. Accomplishments/Planned Programs (\$ in Millions)
 N/A

C. Other Program Funding Summary (\$ in Millions)
 N/A

Remarks

D. Acquisition Strategy
 N/A

E. Performance Metrics
 N/A